Prebiotic bacteriophage containing composition for treatment of gastrointestinal inflammation
AssigneeDeerland Enzymes, Inc.
InventorsJohn Deaton, Ana Maria Cuentas
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method of treating gastrointestinal inflammation such as inflammatory bowel disease (IBS) with a bacteriophage containing composition. The bacteriophage containing composition can be used as prebiotic supplementation and support of the gastrointestinal microflora. This disclosure relates to compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual.
Claims15
A method for reducing Escherichia coli populations in the gut microbiota of a human, comprising orally administering to the human a bacteriophage-containing composition comprising one or more bacteriophages selected from the group consisting of Siphoviridae family and Myoviridae family.
A method for reducing Escherichia coli fecal bacteria populations in the gut microbiota of a human, comprising orally administering to the human a bacteriophage-containing composition comprising one or more bacteriophages selected from the group consisting of Siphoviridae family and Myoviridae family, wherein reduction of E. coli fecal bacteria results in reduction of circulating endotoxins.
Dependencies are inferred from the claim text.